RU2484086C9 - Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты) - Google Patents

Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты) Download PDF

Info

Publication number
RU2484086C9
RU2484086C9 RU2006126797/04A RU2006126797A RU2484086C9 RU 2484086 C9 RU2484086 C9 RU 2484086C9 RU 2006126797/04 A RU2006126797/04 A RU 2006126797/04A RU 2006126797 A RU2006126797 A RU 2006126797A RU 2484086 C9 RU2484086 C9 RU 2484086C9
Authority
RU
Russia
Prior art keywords
atoms
cycle
alkyl
heteroatoms
hydrogen
Prior art date
Application number
RU2006126797/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006126797A (ru
RU2484086C2 (ru
Inventor
Джулиан АДАМС
Юнь Гао
ЭВАНГЕЛИНОС Асимина Т. ГЕОРГЕС
Луи ГРЕНЬЕ
Джеймс Р. ПОРТЕР
Роджер Х. ПЭК
Джеймс Л. РАЙТ
Original Assignee
Инфинити Дискавэри, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34744040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2484086(C9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Инфинити Дискавэри, Инк. filed Critical Инфинити Дискавэри, Инк.
Publication of RU2006126797A publication Critical patent/RU2006126797A/ru
Publication of RU2484086C2 publication Critical patent/RU2484086C2/ru
Application granted granted Critical
Publication of RU2484086C9 publication Critical patent/RU2484086C9/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2006126797/04A 2003-12-23 2004-12-23 Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты) RU2484086C9 (ru)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US53208003P 2003-12-23 2003-12-23
US60/532,080 2003-12-23
US54014204P 2004-01-29 2004-01-29
US60/540,142 2004-01-29
US54738104P 2004-02-23 2004-02-23
US60/547,381 2004-02-23
US56171804P 2004-04-12 2004-04-12
US60/561,718 2004-04-12
US56756504P 2004-05-03 2004-05-03
US60/567,565 2004-05-03
US60628304P 2004-09-01 2004-09-01
US60/606,283 2004-09-01
US62628604P 2004-11-09 2004-11-09
US60/626,286 2004-11-09
US63285804P 2004-12-03 2004-12-03
US60/632,858 2004-12-03
PCT/US2004/043162 WO2005063714A1 (en) 2003-12-23 2004-12-23 Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Publications (3)

Publication Number Publication Date
RU2006126797A RU2006126797A (ru) 2008-01-27
RU2484086C2 RU2484086C2 (ru) 2013-06-10
RU2484086C9 true RU2484086C9 (ru) 2013-08-20

Family

ID=34744040

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006126797/04A RU2484086C9 (ru) 2003-12-23 2004-12-23 Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты)

Country Status (15)

Country Link
US (13) US7282493B2 (enExample)
EP (2) EP2492261B1 (enExample)
JP (2) JP4869077B2 (enExample)
KR (1) KR101154351B1 (enExample)
CN (1) CN102643233B (enExample)
AU (1) AU2004309395C1 (enExample)
BR (1) BRPI0418147A (enExample)
CA (1) CA2547343C (enExample)
DK (1) DK1716119T3 (enExample)
ES (1) ES2409351T3 (enExample)
IL (2) IL175911A (enExample)
NO (1) NO337933B1 (enExample)
PT (1) PT1716119E (enExample)
RU (1) RU2484086C9 (enExample)
WO (1) WO2005063714A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
CN102643233B (zh) 2003-12-23 2015-11-25 无限发现公司 用于治疗癌症的包含苯醌的安沙霉素类似物
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
EP1814392A4 (en) * 2004-11-02 2008-06-11 Conforma Therapeutics Corp METHODS AND COMPOSITIONS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
US10252088B2 (en) 2004-12-02 2019-04-09 Obagi Cosmeceuticals Llc Topical compositions and methods of manufacturing them in specifically treated steel vessels
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
US11457813B2 (en) 2005-03-29 2022-10-04 Martin W. Roche Method for detecting body parameters
RU2007144195A (ru) * 2005-04-29 2009-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них
GB0517886D0 (en) * 2005-09-02 2005-10-12 Biotica Tech Ltd Novel compounds
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070207992A1 (en) * 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
GB0606548D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
US8492370B2 (en) 2006-11-09 2013-07-23 Bristol-Myers Squibb Company Compounds and methods for their production
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101688227B (zh) * 2007-01-26 2013-07-24 科森生物科学公司 通过工程化生物合成制备的大环内酰胺
CN101677991A (zh) * 2007-04-12 2010-03-24 英菲尼蒂发现公司 氢醌安莎霉素制剂
US7851620B2 (en) * 2007-06-07 2010-12-14 Board Of Regents, The University Of Texas System Methods for preparing diazonamides
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
WO2010045442A1 (en) * 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
JP2013510585A (ja) * 2009-11-13 2013-03-28 インフィニティー ファーマシューティカルズ， インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
WO2013074695A1 (en) 2011-11-14 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Hsp90 inhibitors with modified toxicity
WO2017048911A1 (en) * 2015-09-19 2017-03-23 Applied Materials, Inc. Surface-selective atomic layer deposition using hydrosilylation passivation
US10052304B2 (en) 2015-10-12 2018-08-21 University Of Iowa Research Foundation Compositions and methods for cancer therapy
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111A (en) * 1981-09-17 1983-04-07 Takeda Chemical Industries Ltd Macbecin derivatives and their production
WO1993014215A1 (en) * 1992-01-06 1993-07-22 Pfizer Inc. Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120578A (en) 1871-11-07 Improvement in letter-boxes
US123640A (en) 1872-02-13 Improvement in tab-plates of buckles
US745718A (en) * 1903-04-25 1903-12-01 Owen Thomas Dougherty Weight-indicating sliding and spring support for vehicle-bodies.
GB210611A (en) * 1923-01-16 1924-02-07 Clarence Hancock Improved means of heating garden propagating frames, foster mothers and the like
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
JPS5470299A (en) * 1977-11-14 1979-06-05 Takeda Chem Ind Ltd Production of maytansine derivative
JPS5874651A (ja) * 1981-09-17 1983-05-06 Takeda Chem Ind Ltd マクベシン誘導体およびその製造法
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
NZ222695A (en) 1986-11-29 1990-03-27 Ueno Seiyaku Oyo Kenkyujo Kk Synergistic antiviral compositions
US5397584A (en) * 1992-12-09 1995-03-14 Mccormick & Company, Inc. Process for preparing stabilized, partially-dehydrated aromatic plant products
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO1996040265A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000003737A2 (en) 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble drugs and methods for their production
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
AU2001292548B2 (en) 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
DE60213386T2 (de) 2001-03-30 2006-11-23 The United States Of America Represented By The Secretary, Department Of Health And Human Services Geldanamycinderivate zur krebsbehandlung
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005515164A (ja) * 2001-08-06 2005-05-26 コーサン バイオサイエンシーズ， インコーポレイテッド ベンゾキノンアンサマイシン
JP2005504086A (ja) 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
JP2005520795A (ja) * 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
CA2474508A1 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
TW200303363A (en) 2002-02-25 2003-09-01 Upjohn Co Process to prepare and isolate geldanamycin
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
JP2006514994A (ja) 2003-03-13 2006-05-18 コンフォーマ・セラピューティクス・コーポレイション 長鎖および中鎖トリグリセリドを有する医薬製剤
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
CN102643233B (zh) 2003-12-23 2015-11-25 无限发现公司 用于治疗癌症的包含苯醌的安沙霉素类似物
EP1737825A1 (en) 2004-03-26 2007-01-03 Van Andel Research Institute Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
US20100279994A1 (en) 2005-06-21 2010-11-04 Inifinity Discovery, Inc. Ansamycin Formulations and Methods of Use Thereof
EP1897871A4 (en) 2005-06-29 2009-12-09 Kyowa Hakko Kirin Co Ltd ANSAMYCIN BENZENOID DERIVATIVE
CN101360492A (zh) 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101677991A (zh) 2007-04-12 2010-03-24 英菲尼蒂发现公司 氢醌安莎霉素制剂
US9907242B2 (en) 2016-02-18 2018-03-06 Seminis Vegetable Seeds, Inc. Pepper hybrid SV5873HE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111A (en) * 1981-09-17 1983-04-07 Takeda Chemical Industries Ltd Macbecin derivatives and their production
WO1993014215A1 (en) * 1992-01-06 1993-07-22 Pfizer Inc. Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins

Also Published As

Publication number Publication date
US20090088414A1 (en) 2009-04-02
JP2011225614A (ja) 2011-11-10
US20050227955A1 (en) 2005-10-13
CA2547343A1 (en) 2005-07-14
US20090209549A1 (en) 2009-08-20
EP2492261B1 (en) 2015-02-18
KR20060132660A (ko) 2006-12-21
IL206984A0 (en) 2011-07-31
RU2006126797A (ru) 2008-01-27
US7282493B2 (en) 2007-10-16
ES2409351T3 (es) 2013-06-26
US7608613B2 (en) 2009-10-27
US7833997B2 (en) 2010-11-16
US7566706B2 (en) 2009-07-28
AU2004309395B2 (en) 2011-10-06
US20060014731A1 (en) 2006-01-19
US20090069280A1 (en) 2009-03-12
US7375217B2 (en) 2008-05-20
HK1097410A1 (en) 2007-06-22
RU2484086C2 (ru) 2013-06-10
US7361647B2 (en) 2008-04-22
US8703755B2 (en) 2014-04-22
NO20062707L (no) 2006-09-11
US20090062250A1 (en) 2009-03-05
KR101154351B1 (ko) 2012-06-15
US20090208590A1 (en) 2009-08-20
US8252779B2 (en) 2012-08-28
BRPI0418147A (pt) 2007-04-17
EP2492261A1 (en) 2012-08-29
AU2004309395C1 (en) 2012-10-04
US7767662B2 (en) 2010-08-03
IL206984A (en) 2015-02-26
US20090253653A1 (en) 2009-10-08
PT1716119E (pt) 2013-06-04
CN102643233A (zh) 2012-08-22
US20120058982A1 (en) 2012-03-08
IL175911A (en) 2012-01-31
CN102643233B (zh) 2015-11-25
EP1716119A1 (en) 2006-11-02
NO337933B1 (no) 2016-07-11
US7691840B2 (en) 2010-04-06
JP2007528875A (ja) 2007-10-18
CA2547343C (en) 2013-05-14
DK1716119T3 (da) 2013-06-10
US20050288269A1 (en) 2005-12-29
WO2005063714A1 (en) 2005-07-14
US7579337B2 (en) 2009-08-25
AU2004309395A1 (en) 2005-07-14
US20110086110A1 (en) 2011-04-14
US7767663B2 (en) 2010-08-03
JP4869077B2 (ja) 2012-02-01
JP5313308B2 (ja) 2013-10-09
US20060019939A1 (en) 2006-01-26
IL175911A0 (en) 2006-10-05
US8003634B2 (en) 2011-08-23
EP1716119B1 (en) 2013-03-06
US20130203724A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
RU2484086C9 (ru) Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты)
ES2710380T3 (es) Compuestos y usos de los mismos para la modulación de hemoglobina
ES2268876T3 (es) Farmacos hidrosulubles de fenoles impedidos.
JP2007528875A5 (enExample)
EP4365178A1 (en) Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof
ES2670872T3 (es) Polimorfo de una sal de dietanolamina de treprostinil
RU2563638C2 (ru) Способ получения производных морфолинилантрациклина
JP2011225614A5 (enExample)
ES2942468T3 (es) Compuestos que contienen deuterio
ES2337397T3 (es) Ansamicinas de hidroquinona para el tratamiento de tumores del estroma gastrointestinal.
CA2380022A1 (en) Aromatic esters of camptothecins and methods to treat cancers
JP2022529915A (ja) 新規な製剤
ES2937810T3 (es) Derivado de sulfonamida con esqueleto de cumarina
CN106831790A (zh) 7H‑吡咯并[2,3‑d]嘧啶衍生物
ES2628022T3 (es) Derivados de camptotecina con actividad antitumoral
PT89082B (pt) Processo para a preparacao de novos derivados n-(23-vinblastinoilicos) do acido 1-amino-metilfosfonico
EP4104833A1 (en) Ascorbic acid and quinone compound for cancer treatment
WO2018056336A1 (ja) ペメトレキセド製剤
CA2278682C (en) Pyrroloindole derivatives and intermediates in producing the same
JP2003506332A (ja) 経口投与活性のあるビス白金錯体
EP4448107B1 (en) Drug delivery systems based on endoperoxides useful in diagnosis and therapy, and methods thereof
RU2565079C2 (ru) Бензамидные производные, обладающие противораковой активностью, способ их получения и их применение
JPWO2007013490A1 (ja) カンプトテシン類含有水溶液製剤
EP1169303B1 (en) Aryl-chloroalkyl ureas
US20220175973A1 (en) Method for producing radiopharmaceutical and radiopharmaceutical

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090903

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20100818

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20111018

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20121009

TH4A Reissue of patent specification
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161224